

FORWARD LOOKING STATEMENT





This document has been prepared by BluGlass Limited to provide readers with an update of the Company and the Company's technology.

Any statements, opinions, technical data and information, or other material contained in this document, do not constitute commitments, representations or warranties by BluGlass Limited or associated entities, or its directors, agents and employees. Except as required by law, and only to that extent, directors, agents and employees of BluGlass Limited disclaim any loss, claim, demand, damages, costs or expenses of any nature whatsoever arising in any way out of, or in connection with, the information contained in this document.

This document includes certain information which reflects various assumptions, subjective judgment and analysis, and is subject to significant business, economic and competitive uncertainties, risks and contingencies, many of which are outside the control of, and are unknown to, BluGlass Limited. The assumptions may not prove to be correct. Recipients of the document must make their own independent investigations, consideration and evaluations prior to making any decisions to invest in the Company.

Information on Service Addressable Markets (SAM) is based on internal BluGlass modelling and assumptions, both of which depend on successful R&D outcomes and results achieved within estimated timetables. BluGlass recommends a cautious interpretation be taken by investors.





EXECUTIVE SUMMARY — SCALING TO GLOBAL MARKETS



Leading GaN Laser Supplier	 BluGlass is the world's first pure-play gallium nitride (GaN) laser company supplying to the global photonics industry GaN lasers are advanced semiconductor devices essential to the function of a wide variety of applications, including advanced manufacturing, defence, aerospace, navigation, automotive, AR/VR displays, 3-D printing, bio-medical devices, quantum sensing and computing, and more. 			
Large and Rapidly Growing Global Markets with Few Competitors	 Global laser revenue is forecast to surpass US\$25B by 2025*. Driven by growth in high-tech applications, the GaN laser diode segment is rapidly expanding, predicted to reach US\$2.5B in the same period BluGlass is one of a handful of GaN laser diode suppliers able to meet the significant global unmet market for laser diodes. 			
Strategic Partnerships with Defense Primes and Global Companies	 BluGlass partners with globally leading companies, government agencies (US DoD), defence primes, and research universities on large, revenue generating projects to advance and commercialise its products Model provides non-dilutive capital to support the direct-to -market GaN laser business, slower to scale but with greater long-term opportunity. 			
Unique Competitive Advantages to Drive Growth	 World leading DFB laser capabilities for ultra high-precision lasers for next-gen defence, aviation, navigation, and quantum applications Custom manufacturing and development agility means BluGlass is selected by key partners, including the US DoD's Microelectronics Commons Unique IP for novel device architectures that solve critical industry challenges Healthy pipeline of large development agreements and long-term projects in various stages of negotiation. 			
Recent Wins	 US\$5.5M US Department of Defense subcontracts for laser development with North Carolina State University (A\$2.6M + A\$2.9M) A\$1.2M contract with a VC backed start-up developing novel technology in \$5B market opportunity MoU with Applied Energetics to advance laser systems for military and commercial applications A\$1.93M from European after developer customer from transfer of IP rights US\$120k repeat order for GaN lasers. 			
Upcoming Catalysts	 Development contract announcements with key government agencies, defence primes, and OEMs Master supply agreements with development partners 			
Capital Raise	Capital Raise of approximately \$8.3m comprising; A Placement of approximately 180.9m ordinary shares to raise A\$2.3m ("Placement") under existing LR7.1 & 7.1A placement capacit A Share Purchase Plan to eligible shareholders on the same terms as the Placement to raise approximately \$6m ("SPP") 	Ly*		
Use of Funds	 Scaling Product Delivery & Capital Expenditure General Working Capital and cost of the offer 	\$6.8M \$1.5M		

WHO WE ARE: THE LEADING PURE PLAY GaN LASER SUPPLIER



BluGlass is one of only a handful of global GaN laser suppliers, with rapidly growing demand and high-barriers to entry



WHO WE ARE: THE LEADING PURE PLAY GaN LASER SUPPLIER





Launched suite of GaN Visible laser diodes

Products available in underserved wavelengths and flexible form factors to address key customer challenges.



Expert laser and manufacturing team

Highly experienced manufacturing team, led by laser diode veteran Jim Haden.



Growing customer engagement & revenues

BluGlass is partnering with industry leaders, including the US Department of Defense, global defence primes, OEMs, national labs and research institutes, and device manufacturers.



Global operations

Vertically integrated across three production facilities:

Sydney, NSW, Australia

ASX: BLG

- Silicon Valley, California, USA
- Nashua, New Hampshire, USA



Proprietary technology; 58 patents

RPCVD manufacturing process enables novel, brighter and higher efficiency laser diodes.



Few competitors in rapidly growing market

One of just a handful of GaN laser manufacturers globally, with high barriers to entry. BluGlass is only pure-play GaN laser supplier not captive in commoditised markets.



BLUGLASS IN 2025



Global leader in visible lasers for high-fidelity and precision applications

Industry-leading narrow-line width GaN DFB and single mode MOPA lasers

World-record performance

State-of-the-art single-mode GaN laser performance - for next-gen quantum, aerospace & defence applications

Launched gain-chips at Photonics West

Next-generation gain-chips unveiled at the world's largest photonics conference, accelerating industry adoption

Expanding world-leading IP

Strengthening competitive edge with new provisional patents protecting novel power, precision, and tunability architectures

Growing opportunity pipeline

Diverse portfolio of high-value engagements across defence, aerospace, quantum, and medical markets

Tech titan advisory board

Strategic guidance from a world-class advisory board with deep expertise across photonics, semiconductors, and commercial scaling.

Industry is choosing
BluGlass to develop
next-generation power
and precision applications
driving new frontiers in
quantum, defence and
aerospace

GROWING MOMENTUM - \$6M+ IN RECENT CONTRACT WINS





\$2.9M

Won A\$2.9M US Department of Defense (DoD) sub-contract with Microelectronics Commons CLAWS Hub. To advance BluGlass laser capabilities in key dual-use markets: quantum, defence, commercial aviation, bio-medical and sensing

\$1.2M

Entered multi-phased JDA with US semiconductor pioneer to develop novel Photonic Integrated Chips (PICs). Secured A\$1.2M for first phase of development, entered follow-on master supply agreement for commercialisation in ~\$5B by 2030 market.

\$1.9M

Secured single largest customer payment of \$A1.93 million by European wafer customer for transfer of non-laser IP rights, developed under paid foundry contract

MOU

MOU with Applied Energetics to combine high-performance solutions and expertise across a wide range of emerging technologies

GROWING DEMAND AND MARKET VALIDATION







BluGlass' laser offering addresses underserved markets, wavelengths and delivered in flexible form factors.



Dedicated GaN laser supplier

A dedicated GaN laser supplier targeting the quantum, scientific, biotech, defence and industrial markets.



Differentiated offering & novel capabilities

BluGlass' novel capabilities are attracting top-tier strategic partners, progressing through our project pipeline



Development capability

Supporting customer product roadmaps with development capability to power innovative new applications.



Solving our customers greatest challenges

Packaging and customisation flexibility to reduce customer integration costs, solving key challenges.

BluGlass' go-to-market strategy has been validated by strong customer demand and market recognition.

Our partners are choosing to work with us to solve challenges, develop novel capabilities, and create new markets.

LEADERSHIP TEAM: DEEP LASER INDUSTRY EXPERTISE



BOARD OF DIRECTORS



James Walker
NON-EXECUTIVE CHAIR
Experienced technology
commercialisation leader; Chartered
Accountant



Jean-Michel Pelaprat NON-EXECUTIVE DIRECTOR Co-founder of blue-laser pioneer, NUBURU; 30 years' semiconductor experience



Stephe Wilks
NON-EXECUTIVE DIRECTOR
Seasoned corporate executive; proven track record in high growth and disruptive industries



Vivek Rao
NON-EXECUTIVE DIRECTOR
Global semiconductor equipment
specialist; Executive VP and COO of
SPT Micro-Technologies

MANAGEMENT TEAM



CEO
Veteran laser expert with 30 years' experience; demonstrated experience transforming advanced tech businesses



COO & CTO

Product development and technology commercialisation specialist with experience through-out photonics industry

Dr Ian Mann



Brad Siskavich
EXECUTIVE VP
More than 25 years' experience developing and commercialising new compound semiconductor and laser technologies



Samuel Samhan
CFO
Highly-credentialled finance
executive with more than 20 years'
experience



Stefanie Winwood
HEAD OF CORPORATE & IR
Strategic marketing and Investor
Relations professional with more
than 15 years' experience in hightech and semiconductor sectors



Carol Huang
HEAD OF WAFER FAB
OPERATIONS
GaN product and process
development expert experienced in
bringing products from conception to
the market.

INDUSTRY ADVISORY BOARD — ACCELERATING TECHNICAL & COMMERCIAL ADVANCEMENT


INDUSTRY ADVISORY BOARD



Steven DenBaars

Professor DenBaars is one of the world's foremost experts in GaN laser development and commercialisation.

Co-founded **Soraa Laser Diode** and oversaw its acquisition by Kyocera Corporation for \$450 million in 2021, Serves on the Board of Directors of Aeluma and SmartKem and is a Scientific Advisor to Seoul Semiconductor, the third-largest LED company globally.



Richard Craig

Dr Craig led multiple semiconductor laser companies, both venture funded start-ups and large publicly traded industry leaders.

Developed and managed the laser pump business that led to the \$41B acquisition of Spectra Diode Lasers by JDS Uniphase, representing the largest tech merger to date at the time of announcement in 2000.

CONSORTIUM ADVISORS

Leverage our expert advisors supporting us at SSLEEC & CLAWS

- Request profiles added to our People page on BluGlass website, under 'Consortium Advisors'
- Add profiles to our Investor Presentation material
- Include in the Industry Advisory Board announcement to market





Prof. Shuji Nakamura Nobel Laureate, Physics

Widely recognized as pioneer in light emitters based on wide-bandgap semiconductors, Nakamura continues to focus on development of GaN thin film technology for the developments of high efficient Nitride-based LEDs and laser diodes.



Prof. John Muth

- · Director CLAWS Hub
- Co-Founded NSF Engineering Research Center ASSIST
- Founded and Principal Investigator for PowerAmerica
- Served as Jefferson Science Fellow with USAID



Prof. Fred Kish

- Deputy Director CLAWS Hub
- Ex Infinera Corporation & Hewlett Packard
- Fellow of the National Academy of Inventors, Optica and IEEE, member of the National Academy of Engineering.



LASER TECHNOLOGY UNDERPINS GLOBAL MEGATRENDS



US \$38B Market

Defense & Space

US\$11B

Defence laser systems market by 2033

Quantum & Sensing

US \$6B

Quantum sensing market by 2030

Healthcare & BioTech

\$21B

Market by 2033

Source: Straits Research, Gartner Insights, Goldman 2024

Source: McKinsey & Company 2024

Source: Spherical Insights 2024, The Business Research 2024

DEFENCE LASER SYSTEMS - A US \$11B OPPORTUNITY BY 2033




















Source: Straits Research, Gartner Insights, Goldman 2024

QUANTUM SENSING OPPORTUNITY



The quantum sensing market is projected to experience explosive growth to reach US\$1 billion by 2030 and \$6 billion by just 2040, as its advantages both disrupt existing at the same time as forging new markets that rely on sensor technology, according to recent McKinsey analysis.





Quantum sensing

\$1B-\$6B

estimated market size by 2040

\$0.7B invested as of Dec 2023

48 start-ups as of Dec 2023

QUANTUM COMPUTING OPPORTUNITY






Quantum computers hold the potential to drive remarkable progress in industry & high-tech, with companies already exploring capabilities to develop innovations such as lighter, more powerful batteries for EVs, new medicines, cryptography, and artificial intelligence.



Visible lasers play key roles in creating Qubits (rather than ordinary bits), trapping, cooling, and decelerating atoms and ions.




Multiple tunable lasers with multiple frequencies are needed to interact with key materials for creating and controlling qubits.



\$1.2B - \$170B

2024 market size

Estimated market size by 2040




HEALTHCARE & BIOTECH OPPORTUNITY



Global medical laser systems market is expected to reach US\$ 16B by 2033.

As the need for more personalised medicine increases, researchers are finding that new laser wavelengths and integrated multiwavelength laser light engines are enabling high-dimensional analysers with improved performance.

Source: Spherical Insights





NUBURU

















COMPUTING & SENSING

















KEY INDUSTRY PLAYERS BY SEGMENT









Panasonic



SAMSUNG





BIOTECH

modulight























COMPETITIVE LANDSCAPE

		A SUCILIA	OCDAM		nuvoTon	
	•••	NICHIA	OSRAM	SHARP	SLDLASER	新唐科技
Characteristics	Pure-play GaN laser challenger	Global conglomerate and market leader	Global lighting company	Global consumer electronics company	Japanese owned white light laser company	Taiwanese laser company
Pure-play GaN laser company						
Full-suite GaN manufacturing capability						
Mature product portfolio						
Market leadership	GaN DFB lasers, MOPAs, SOAs	High-power MM lasers	LED/GaN lasers	Blue-ray	High-power white light	
Manufacturing agility and flexibility						
Custom development and fast prototyping						
Flexible form factors						
Custom integration						
RPCVD & AAG Tunnel Junction Technology						
Novel GaN architectures; DFB, Gain Chips						
US DoD/ AUKUS Defence Contract Eligibility						





MICROELECTRONICS COMMONS ACCELERATES BLG's COMMERCIAL DISCUSSIONS

BLG IS A COMMERCIAL PARTNER IN CLAWS



- US Department of Defense allocated \$2B to 8 regional Hubs in ME Commons
- CLAWS Hub awarded US \$63M for core development work in FY24 & FY25



BLG AWARDED AU\$5.5M

- BluGlass awarded A\$2.6 & \$2.9M for core development contracts across FY24 & FY25.
 - Contracts for FY26-FY28 TBA



Five-year US Department of Defense (DoD) program established to accelerate the Lab-to-Fab transition & produce next-gen microchips at scale



Program helps unlock government, prime, & commercial relationships with key US players across next gen critical defence capabilities, dual-use, aerospace, sensing, & quantum applications

CLAWS HUB LEAD & MEMBERS

LEAD



MEMBERS

ADROIT MATERIALS




















QUANTUM & SCIENTIFIC





BluGlass' customers include leading OEMs, national labs and research organisations, to disruptive start-ups across our target market verticals







Solving customer challenges
BluGlass is helping customer's develop novel

applications through rapid prototyping and custom development inc: custom wavelengths, novel designs, custom integrations, and flexible form-factors



BIOTECH & MEDTECH



Growing our project & revenue pipeline

BluGlass lasers are being qualified in customer applications to validate performance and lifetime



Validated our differentiated product offering

Our customers are purchasing both off-the-shelf standard products and highly customized products in flexible form factors, validating our flexible manufacturing offering and full-suite capability





PROJECT-TO-PRODUCT REVENUE PIPELINE & OPPORTUNITY



BluGlass' project pipeline is gaining significant momentum with diverse opportunities in negotiation in the pipeline

26*project opportunities in pipeline representing US\$90-100M in project value

Project Pipeline



Follow-on Revenues

Projects lead to large-scale manufacturing contracts & product revenues in \$2B GaN laser serviceable market

Growing pipeline of opportunity

Initial evaluation to advanced negotiations with diverse customers and partners

Proposals & tenders:

Form key industry partnerships with defense primes, government agencies, OEMs and large commercial manufacturers, & well-funded innovative start-ups

Contract negotiations

Establish leadership and develop novel capabilities in high-growth markets: quantum, defence, aviation, scientific, and biomedical

Follow-on large-scale revenues

Securing long-term, large —scale revenue generating projects (e.g. ME Commons) and entering follow-on commercial manufacturing contracts

The project pipeline includes opportunities at various stages of engagement. Negotiations with OEMs, prime contractors, and government agencies can take many months or years to mature, and not all engagements will result in revenue-generating contracts.

KEY CATALYSTS & MILESTONES



Enter development contracts

Convert opportunities in pipeline currently worth US\$90-100m to revenue generating projects & contract wins with primes, OEMs, government agencies, & sub-primes

Renew existing annual contracts

Enter years 3-5 of Microelectronics Commons (CLAWS Hub) contract

Commence Phase 2 of JDA with commercial development partner

Form strategic partnerships with top tier customers

Establish relationships with key government agencies, defence primes, OEMs, and market leaders

Advance technical capabilities


Install state-of-the-art
equipment to enhance
manufacturing & operations
for high-fidelity product lines
(quantum, aerospace,
defence)

Launch new high ASP products

Launch advanced capabilities & high-fidelity product lines (DFBs, gain-chips)

Secure IP & competitive advantages

Key patents granted securing leadership in precision & high-fidelity applications



Build revenue scale with follow-on-contracts

Development contracts are intended to lead to large, long term master supply agreements with development partners

BUILDING SIGNIFICANT BUSINESS MOMENTUM



Gaining Business
Momentum

A\$6M+

In recent contract wins with key partners across key market verticals

Key Partnerships

Including the

US DoD

As part of the Microelectronics Commons, CLAWS Hub, inc. GE, Coherent, MACOM, NSCU **Significant Growth**

133%

133% three-year revenue CAGR.

A\$4.6m revenue in FY24, with record revenue expected in CY25

Growing Pipeline of Opportunity

\$90-100m

of revenue opportunity across 26 Key Projects

BluGlass' project pipeline is growing with diverse opportunities



INVESTMENT OPPORTUNITY



BluGlass is undertaking a capital raising of up to approximately A\$8.3m via a Placement and Share Purchase Plan

Placement	 Single tranche non-underwritten placement to sophisticated, professional and institutional investors to raise up to approximately ~\$2.3m (before costs) (Placement) Approximately 180.9 million new, fully paid ordinary BluGlass shares (New Shares) to be issued under the Placement, representing approximately 9.0% of existing ordinary shares on issue, utilising the Company's available placement capacity under ASX Listing Rules 7.1 and 7.1A
Offer Price	 Placement Offer Price of \$0.013 per New Share represents a: 18.75% discount to the last close of \$0.016 on 28 April 2025 25.5% discount to the 10-day volume-weighted average price (VWAP) of \$0.0174
Share Purchase Plan	 The Company will offer eligible shareholders the opportunity to participate in a Share Purchase Plan (SPP) and apply for up to \$100,000 of New Shares, to raise an additional \$6.0 million and will be offered at the lower of: \$0.013 per New Share, being the price paid under the Placement; and 2.5% discount to the VWAP of the Company's shares traded on the ASX during the five trading days up to the closing date of the SPP, rounded to the nearest half cent Record date for determining eligibility for the SPP is 7:00pm on Wednesday, 30 April 2025 Further details in relation to the SPP, including the scale-back policy, will be provided to eligible shareholders in a transaction-specific prospectus. Issue of SPP shares are subject to shareholder approval at an extraordinary general meeting of the Company to be held on or around Monday, 9 June 2025. The Company reserves the right to accept over subscriptions under the SPP up to a total of \$3m subject to ASX Listing Rules and Corporations Act 2001 (Cth).
Attaching Options	 Every one (1) New Share under the Placement and SPP will receive one (1) unlisted attaching option (Attaching Option). Attaching options will be exercisable at A\$0.013 and have an expiry date on the earlier of: 31 May 2026; and the date being 30 days from the date on which the Company announces a contract win from a Tier 1 company for a total contract value of > \$3m (if at all). Upon exercise, every one (1) Attaching Options will receive one (1) piggyback option, which is exercisable at A\$0.019 and an expiry date of 31 May 2028. It is intended that the Piggyback Options will be listed, subject to ASX spread requirements. Attaching Options are subject to shareholder approval at an extraordinary general meeting of the Company to be held on or around 9 June 2025.
Use of Proceeds	 Offer proceeds to be applied towards servicing new and existing development contracts, scaling product delivery, capital expenditure for high-fidelity product lines, general working capital and cost of the offer Pro Forma cash position as at 31 March 2025 of \$7.2 m (excluding costs of the offer)
Lead Manager, and Bookrunner	Bell Potter Securities Limited is acting as Lead Manager and Bookrunner to the Placement & SPP SLIDE 27
Ranking	New Shares issued under the Placement will rank pari-passu with existing fully paid ordinary shares on issue

TIMETABLE: Capital Raising Offer Timetable



Key Dates	
SPP record date	Wednesday, 30 April 2025
Announcement of Capital Raising	Thursday, 1 May 2025
Settlement of Placement	Wednesday, 7 May 2025
Allotment and normal trading of Placement Shares on the ASX	Thursday, 8 May 2025
SPP Opens	Thursday, 8 May 2025
EGM to approve issue of SPP shares, SPP options and Placement options	On or around Monday, 9 June 2025
SPP Closes	Tuesday, 10 June 2025
Allotment of SPP shares, SPP options and Placement attaching options (subject to shareholder approval)	On or around Thursday, 12 June 2025

KEY RISKS



Risk	Risk Description
Loss of key management personnel	BluGlass' ability to effectively execute its business strategy depends upon the performance and expertise of its key management personnel. Any loss of key management personnel, any delay in the replacement of any key management personnel, or any extended period where key management personnel are unable to work will adversely affect BluGlass' operations and future performance.
Development and commercialisation of technologies	The success of BluGlass will be impacted by the successful development and commercialisation of its technologies. For instance, BluGlass' RPCVD technology may fail to meet competitive specifications. Should the development not be completed in accordance with BluGlass' specifications or should the results of further testing indicate technology performance is below market requirements, BluGlass will have to expend additional time and resources to rectify any outstanding issues which will delay the commercialisation of the company's advanced roadmaps. BluGlass may also experience difficulty in raising capital if such technology-related milestones are not achieved.
Product liability and uninsured risks	BluGlass is exposed to potential product liability risks, inherent in the research and development, manufacturing, marketing and use of its products or products. Further, BluGlass is exposed to the risk of catastrophic loss to necessary laboratory equipment, computer equipment or other facilities, which would have a serious impact on BluGlass' operations.
Intellectual property	BluGlass relies upon a combination of patents, know-how, trade secret protection and confidentiality agreements to protect its technologies. Legal standards relating to the validity, enforceability and scope of protection of intellectual property rights are uncertain. Effective patent, trade mark, copyright and trade secret protection may not be available to BluGlass in every country in which its products may be sold. Accordingly, despite its efforts, BluGlass may not be able to prevent third parties from infringing upon or misappropriating its intellectual property.
Competition	The industry in which BluGlass is involved is subject to increasing domestic and global competition which is fast-paced and fast-changing. For instance, new technologies could result in BluGlass not being differentiated to other similar offerings. The size and financial strength of some of BluGlass' competitors may make it difficult for it to maintain a competitive position in the technology market. In particular, BluGlass' ability to acquire additional technology interests could be adversely affected if it is unable to respond effectively and/or in a timely manner to the strategies and actions of competitors and potential competitors or the entry of new competitors into the market. This may in turn impede the financial condition and rate of growth of BluGlass.

INTERNATIONAL OFFER RESTRICTIONS



New Zealand

This document has not been registered, filed with or approved by any New Zealand regulatory authority under the Financial Markets Conduct Act 2013 (the "FMC Act"). The New Shares are not being offered or sold in New Zealand (or allotted with a view to being offered for sale in New Zealand) other than to a person who:

- is an investment business within the meaning of clause 37 of Schedule 1 of the FMC Act;
- meets the investment activity criteria specified in clause 38 of Schedule 1 of the FMC Act;
- is large within the meaning of clause 39 of Schedule 1 of the FMC Act;
- is a government agency within the meaning of clause 40 of Schedule 1 of the FMC Act; or
- in other circumstances where there is no contravention of the disclosure requirements of the FMC Act.

Hong Kong

WARNING: This document has not been, and will not be, registered as a prospectus under the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, nor has it been authorised by the Securities and Futures Commission in Hong Kong pursuant to the Securities and Futures Ordinance (Cap. 571) of the Laws of Hong Kong (the "SFO"). No action has been taken in Hong Kong to authorise or register this document or to permit the distribution of this document or any documents issued in connection with it. Accordingly, the New Shares have not been and will not be offered or sold in Hong Kong other than to "professional investors" (as defined in the SFO and any rules made under that ordinance).

No advertisement, invitation or document relating to the New Shares has been or will be issued, or has been or will be in the possession of any person for the purpose of issue, in Hong Kong or elsewhere that is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to the New Shares that are or are intended to be disposed of only to persons outside Hong Kong or only to professional investors (as defined in the SFO and any rules made under that ordinance). No person allotted New Shares may sell, or offer to sell, such securities in circumstances that amount to an offer to the public in Hong Kong within six months following the date of issue of such securities.

The contents of this document have not been reviewed by any Hong Kong regulatory authority. You are advised to exercise caution in relation to the offer. If you are in doubt about any of the contents of this document, you should obtain independent professional advice.

Singapore

This document and any other materials relating to the New Shares have not been, and will not be, lodged or registered as a prospectus in Singapore with the Monetary Authority of Singapore. Accordingly, this document and any other document or materials in connection with the offer or sale, or invitation for subscription or purchase, of New Shares, may not be issued, circulated or distributed, nor may the New Shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore except pursuant to and in accordance with exemptions in Subdivision (4) of Division 1, Part 13 of the Securities and Futures Act 2001 of Singapore (the "SFA"), or as otherwise pursuant to, and in accordance with the conditions of any other applicable provisions of the SFA.

This document has been given to you on the basis that you are (i) an existing holder of the Company's shares, (ii) an "institutional investor" (as defined in the SFA) or (iii) an "accredited investor" (as defined in the SFA). In the event that you are not an investor falling within any of the categories set out above, please return this document immediately. You may not forward or circulate this document to any other person in Singapore.

Any offer is not made to you with a view to the New Shares being subsequently offered for sale to any other party. There are on-sale restrictions in Singapore that may be applicable to investors who acquire New Shares. As such, investors are advised to acquaint themselves with the SFA provisions relating to resale restrictions in Singapore and comply accordingly.





WHAT WE DO: OFFERING THE WORLD'S EASIEST TO USE Gan LASER LIGHT

BluGlass' vertically integrated laser offering has been designed to meet the market and solve our customers biggest challenges



Plug & Play & Custom Lasers



Offering underserved and custom wavelengths from 400nm-525nm



Single-mode and multi-mode products



Enhanced designs and novel device architectures for higher-power, higher-brightness lasers



Vertically integrated from design and epitaxy to packaging and testing

BluGlass' Form Factor Offerings

Flexible form factors will revolutionize how our customer use GaN laser light



Single emitters/Photonic Integrated Circuits (PICs)



Laser diode bars



Chips-on-submounts (CoS)



TO Cans (various sizings)




C-Mounts, F-Mounts, Butterfly Pins




Multi-chip Modules/Arrays

BLUGLASS INVESTOR PRESENTATION, APRIL 2025



ESTIMATED HORIZON OF QUANTUM TECHNOLOGIES — QUANTUM SENSING IS HERE







BIO-PHOTONICS

GaN DFB LASER APPLICATIONS






GaN DFB Benefits

- Precise wavelength, control, and tuning
- Ultra-narrow linewidth
- High spectral purity
- Low relative intensity noise
- Enhanced stability
- Improved measurement and sensing accuracy using atomic level interactions

WHAT IS A DFB LASER


	Multi-Mode Laser	Single-mode (SM) laser	DFB Laser	SM + SOA	MOPA
	4	\Leftrightarrow			
Features	High-power, high- brightness broad light	Lower-power, bright light in single phase, with narrow linewidth	Ultra-precise near single frequency light	Amplifies the benefits (power)	Amplifies the benefits of SM & DFB lasers in higher-relative
Advantages	High absorption in key metals	Spectral purity, precision	Precise wavelength control and ultra narrow linewidth for atomic, or cellular, scale interaction	of the single- mode device in two separate chips (improved signal-to-noise)	power in one monolithic chip (improved signal- to-noise compact design – lower cost)
Applications	Industrial wielding, materials processing, 3D printing, advanced manufacturing	DNA sequencing, bio-medical applications, sensing, AR/VR	Quantum sensing, bio-sensing, quantum computing, quantum communications	Advanced quantum, aviation, defence applications	Advanced quantum, aviation, defence applications

Multi-Mode, Single-Mode, & DFB Lasers









MARKET DRIVERS - THE ADVANTAGES OF GaN LASER DIODES



Visible GaN visible and UV laser diodes have many advantages over traditional infrared lasers



GaN light interacts favorably with quantum and organic materials (viruses, bacteria, cancer cells), and water/atmosphere



Cleaner, faster welding, 3D-printing, and materials processing



Tighter beam focus and improved efficiency



Higher precision manufacturing, enabling increasingly advanced technology applications




Visible light has higher absorption in key industrial metals



Source: NASA, 1969


DEFENCE & AEROSPACE - \$11B BY 2033

GaN Wavelengths for Defence & Aerospace




M. Corato-Zanarella et al., Nat. Photon., 17, 157-164 (2023)

Quantum Computing, Cryptography & Al



Quantum Clocks & Quantum Sensing



Chauhan, N., et al. Nat Commun 12, 4685 (2021)

LiDAR detecting
Clear Air Turbulence (CAT)



Underwater LiDAR & Comms






QUANTUM: GaN LASERS PRODUCE ESSENTIAL HIGH-ENERGY LIGHT

Scale up in volume, down in size, increase fault-tolerance

Benchtop Scale 8'x10'




NPL Strontium Lattice Clock (2023)

GaN Wavelengths for Quantum
360 380 400 420 440 460 480 500 520 540

Quantum optics,
M. Corato-Zana alla et al., Nat. Photon., 17, 157-164 (2023)

Large Current Scale



Too error-prone to solve commercially valuable problems

570 rom
570 ro

and


Chip Scale 4 x 6 mm

photonics promise improved

computers employing low-noise technology

error-corrected

N. Chauhan et al., Opt. Exp., 30 5 (2022)



PSI-Quantum Website

Scale

PC-Board Size

GaN

tolerance

Rack Mount Computer Size






quantum

BIO-MED & BIO-TECH

- Advances in robotic surgery
- DNA sequencing
- Cancer detection and identification
- Blood sensing
- Wound healing



GaN Wavelengths for bio-med & bio-tech



STERILISATION

UV light at wavelengths between 200 and 280 nanometers has been found to have a high rate of disinfection efficacy (>99.9%)

Frequency doubling of Violet (400 nm) to Green (530 nm) GaN Laser diodes yields UV-C 200 to 265 nm

- UV-C light penetrates the cell walls of microorganisms and damages their DNA and RNA, preventing them from replicating
- Broad-Spectrum Efficacy: UV-C light is effective against various pathogens, including antibioticresistant bacteria and viruses
- The range of UV-C light considered safer for humans is specifically far-UVC light (207 to 222nm)







